viewCellmid Limited

Cellmid appoints Dr Bryce Vissel as chairman of scientific advisory board


Cellmid Limited (ASX:CDY) has appointed award winning researcher Dr Bryce Vissel as chairman of its scientific advisory board to guide efforts to translate its robust science into meaningful patient outcomes.

Vissel is currently the Head of the Neurodegenerative Diseases research group at the Garvan Institute of Medical Research.

He is also Conjoint Senior Lecturer at St Vincent's Clinical School, Faculty of Medicine, University of New South Wales.

Prior to that Dr Vissel worked for a decade at the highly prestigious Salk Institute in La Jolla, California, the world’s leading neuroscience laboratory.   

He was recruited by the Garvan Institute to Australia from California’s Salk Institute to establish and lead research in brain and spinal cord disorders and repair.

Dr Vissel’s research has been widely recognised internationally, and he has received a number of awards, including the prestigious Fulbright award, a Liebermann award and a BIOFIRST award.

He has published more than 50 peer-reviewed papers, many in top tier journals.

Maria Halasz, chief executive officer, said:

“Dr Vissel is a world-class researcher and his outstanding medical research experience will be invaluable in guiding Cellmid’s therapeutic development programs toward clinical success.

Dr Vissel added:

“Cellmid’s sharp focus on midkine underpins a range of therapeutic development programs for the company. This is because manipulating midkine therapeutically offers important potential for treating a range of diseases.

“My goal is to help realise this potential so that patients can benefit from the robust science underlying the company’s drug development programs.”

Last month, the company was issued a Notice of Allowance for a U.S. patent covering its lead humanised antibody CAB102 for the treatment of cancer.

This follows on patents already in force in Europe, Australia and Japan.

Cellmid holds the most significant intellectual property assets related to MK worldwide.
Its patent portfolio currently includes 88 patents in 21 patent families, which cover use of MK and anti-MK agents for therapeutic purposes in a number of diseases, as well as the use of MK as a diagnostic marker in cancer and other disorders.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Cellmid Limited

Price: 0.12 AUD

Market: ASX
Market Cap: $15.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...



Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

2 min read